Semax — clinical evidence
Assessed outcomes with certainty ratings, contributing trials and the reasoning for each rating.
§3Clinical evidence
§3.1Cognitive performance and neuroprotection
Anchor outcome. Domain-specific cognitive test scores.
Effect as recorded. Russian clinical studies report functional improvement after ischaemic stroke and in cognitive disorders; not extractable to the Institute's standard from the available reports.[1,2]
Certainty. Very low certainty Downgraded to very low for risk of bias and reporting limitations rather than for absence of studies. The Institute distinguishes these two reasons for a low rating and states which applies in every assessment.
Contributing trials. SEMAX-RU-STROKE · SEMAX-RU-COGNITIVE. Full structured abstracts are published for each.
Full evidence extract for cognitive performance and neuroprotection · Indication assessment
§3.2Sleep initiation and maintenance disorders
Anchor outcome. Sleep-onset latency.
Effect as recorded. No assessable randomised evidence identified; —.[2,3]
Certainty. Very low certainty —
Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.
Full evidence extract for sleep initiation and maintenance disorders · Indication assessment
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256
- Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge SM, Emberson JR, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366:l4898. doi:10.1136/bmj.l4898 · PMID 31462531
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.